Abstrato

A current evaluation of hypo pharyngeal carcinoma.

Pape Debaene

A small percentage of all head and neck cancers, or about 3%, are hypo pharyngeal malignancies. With a reported 5-year overall survival rate of about 30–35%, hypo pharyngeal carcinoma has one of the worst prognoses of all head and neck malignancies. Therapy-related toxicity and the requirement for surgical salvage continue to rule this disease's landscape. With an emphasis on the development of an organ sparing paradigm, we set out to present a thorough overview of the existing management concepts, recent literature, and evidence-based therapeutic choices surrounding treatment for hypo pharyngeal squamous cell carcinoma in this.